These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8950367)

  • 1. Age-specific prostate-specific antigen: a reassessment.
    Etzioni R; Shen Y; Petteway JC; Brawer MK
    Prostate Suppl; 1996; 7():70-7. PubMed ID: 8950367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
    Schröder FH; Roobol-Bouts M; Vis AN; van der Kwast T; Kranse R
    Urology; 2001 Jan; 57(1):83-90. PubMed ID: 11164149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
    Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
    J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen.
    Lodding P; Aus G; Bergdahl S; Frösing R; Lilja H; Pihl CG; Hugosson J
    J Urol; 1998 Mar; 159(3):899-903. PubMed ID: 9474178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies.
    Etzioni R; Cha R; Cowen ME
    J Urol; 1999 Sep; 162(3 Pt 1):741-8. PubMed ID: 10458357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass screening of prostate cancer in Changchun City of China.
    Li X; Tsuji I; Kuwahara M; Zhang H; Wang H; Zhang L; Ji G; Zhao X
    Int Urol Nephrol; 2004; 36(4):541-8. PubMed ID: 15787333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
    Catalona WJ; Smith DS; Ornstein DK
    JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer screening by prostate-specific antigen (PSA); a relevant approach for the small population of the Cayman Islands.
    Jyoti SK; Blacke C; Patil P; Amblihalli VP; Nicholson A
    Cancer Causes Control; 2018 Jan; 29(1):87-92. PubMed ID: 28918559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.
    Carter HB; Epstein JI; Chan DW; Fozard JL; Pearson JD
    JAMA; 1997 May; 277(18):1456-60. PubMed ID: 9145718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan.
    Takechi H; Ito K; Yamamoto T; Miyakubo M; Ohi M; Suzuki K
    Urology; 2008 Nov; 72(5):1111-5. PubMed ID: 18342926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.
    Törnblom M; Norming U; Adolfsson J; Becker C; Abrahamsson PA; Lilja H; Gustafsson O
    Urology; 1999 May; 53(5):945-50. PubMed ID: 10223488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
    Bokhorst LP; Zhu X; Bul M; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1654-60. PubMed ID: 23043563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer.
    Candas B; Cusan L; Gomez JL; Diamond P; Suburu RE; Lévesque J; Brousseau G; Bélanger A; Labrie F
    Prostate; 2000 Sep; 45(1):19-35. PubMed ID: 10960839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performance of malignant prostatic cells detection in blood for early detection of prostate cancer: comparison to prostatic biopsy.
    Murray NP; Reyes E; Tapia P; Orellana N; Dueñas R; Fuentealba C; Badinez L
    Arch Esp Urol; 2011 Dec; 64(10):961-71. PubMed ID: 22228894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less.
    Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
    Prostate; 2003 Sep; 57(1):8-13. PubMed ID: 12886518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project.
    Littrup PJ; Kane RA; Mettlin CJ; Murphy GP; Lee F; Toi A; Badalament R; Babaian R
    Cancer; 1994 Dec; 74(12):3146-58. PubMed ID: 7526969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer screening in the fit Chilean elderly: a head to head comparison of total serum PSA versus age adjusted PSA versus primary circulating prostate cells to detect prostate cancer at initial biopsy.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
    Asian Pac J Cancer Prev; 2015; 16(2):601-6. PubMed ID: 25684494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.